Atossa THERAPEUTICS, Inc. (ATOS) intrinsic value & 10-year financials
Atossa THERAPEUTICS, Inc. (ATOS) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.91
- Market cap
- $25.1M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -612.0%
- Free cash flow (FY2025)
- -$29.8M
ATOS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$34.8M | -$4.04 | -$29.8M | — | -67.0% |
| FY2024 | — | -$25.5M | -$0.20 | -$21.0M | — | -34.0% |
| FY2023 | — | -$30.1M | -$0.24 | -$21.0M | — | -30.0% |
| FY2022 | — | -$27.0M | -$0.21 | -$20.8M | — | -21.6% |
| FY2021 | — | -$20.6M | — | -$16.5M | — | -24.8% |
| FY2020 | — | -$17.8M | — | -$11.6M | — | -2492.8% |
| FY2019 | — | -$17.2M | — | -$9.1M | — | -2946.4% |
| FY2018 | — | -$11.4M | — | -$9.1M | — | -145.3% |
| FY2017 | — | -$8.1M | — | — | — | -152.4% |
| FY2016 | — | -$6.4M | — | — | — | -205.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ATOSSA THERAPEUTICS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ATOSSA THERAPEUTICS, INC. has historically struggled to out-earn its cost of capital, averaging just -27.2% ROIC.
ATOSSA THERAPEUTICS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
ATOSSA THERAPEUTICS, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.